Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ecoviva
- Development stage
- Unknown
- Lead developer
- Tablets India
- Modality
- Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Ecoviva is a probiotic nutraceutical product line developed and marketed by Tablets India Limited. It contains the specific yeast-based probiotic strain *Saccharomyces boulardii* CNCM I-3799, typically formulated at a strength of 5 billion CFU. Ecoviva is primarily indicated for the management of various gastrointestinal disorders, including rotaviral diarrhea, antibiotic-associated diarrhea (AAD), and the restoration of gut microbiota balance. Its mechanism of action involves competing with pathogenic bacteria for nutrients and adhesion sites on the intestinal mucosa, producing antimicrobial substances, and enhancing the host's intestinal barrier function and immune response. The product is available in multiple oral dosage forms, such as tablets, sachets, drops, and dry syrups, to accommodate different patient populations, including pediatric and adult users.
- Brand names
- Ecoviva
- Other names
- Saccharomyces boulardii CNCM I-3799
Beyond the preview
Go deeper on Ecoviva.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Ecoviva.